Burke Steven Keith
SEC Form 4 insider trading activity
Burke Steven Keith has filed 3 SEC Form 4 filings (5 transaction rows) across 2 companies, including SCYX, AKBA, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Sep 22, 2026.
On the most recent filing, Burke Steven Keith is listed as SVP, Chief Medical Officer at Akebia Therapeutics, Inc. Inside the rolling window, Burke Steven Keith reported no open-market purchases and 1 open-market sale totaling $94K in AKBA.
Companies traded
Other insiders at SCYX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$94K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Burke Steven Keith made?
Burke Steven Keith has filed 3 SEC Form 4 filings (5 transaction rows) across 2 companies, including SCYX, AKBA since 2026.
Which companies does Burke Steven Keith trade?
Burke Steven Keith has filed SEC Form 4 disclosures for 2 companies, including SCYX, AKBA.
When was Burke Steven Keith's most recent SEC Form 4 filing?
Burke Steven Keith's most recent SEC Form 4 filing on Tracefour is dated Sep 22, 2026.
What is Burke Steven Keith's total buy and sell value in the current window?
Inside the rolling retention window, Burke Steven Keith bought $0 and sold $94K based on SEC Form 4 filings.
What was Burke Steven Keith's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 67,658 AKBA shares on 2026-02-02, worth $94K, per SEC Form 4 filings.